Paxlovid didn’t short­en Covid symp­toms in vac­ci­nat­ed adults, full tri­al re­sults con­firm

Last year
Pharma
FDA+

Judge of­fers ear­ly win for Ar­bu­tus as Mod­er­na vac­cine patent spat heats up

Last year
Pharma
Law

Sanofi ends al­most all state per­son­al in­jury law­suits over Zan­tac with undis­closed set­tle­ment

Last year
Pharma
Law

eF­FEC­TOR's lead lung can­cer pro­gram falls through, stock crash­es

Last year
R&D

Ex­perts ap­plaud Amy­lyx for keep­ing its promise to with­draw ALS drug Re­lyvrio af­ter tri­al fail­ure

Last year
Pharma

Can­del’s promis­ing Ph2 da­ta in pan­cre­at­ic can­cer; Mi­cro­bio­me biotech rais­es £27M

Last year
News Briefing

Cure­Vac re­leas­es mixed in­ter­im Phase 2 da­ta for sea­son­al flu vac­cine

Last year
R&D

Why a Medtron­ic ex­ec thinks a con­ver­gence of med tech and con­sumer tech is com­ing

Last year
Health Tech

No­var­tis to make com­mer­cial Carvyk­ti; Re­ci­pharm di­vests sev­en fa­cil­i­ties; Lil­ly’s Zep­bound in short­age 

Last year
Manufacturing

Ex­clu­sive: Ex-Re­cur­sion team launch­es Leash Bio, chal­leng­ing AI field with its bet on need­ing more da­ta

Last year
Financing
AI

Amy­lyx to vol­un­tar­i­ly with­draw ALS drug Re­lyvrio af­ter Phase 3 fail, will lay off around 70%

Last year
People
Pharma

Ex­clu­sive: Jim Wil­son start­up gets FDA green light for first test of gene edit­ing in ba­bies

Last year
R&D
Cell/Gene Tx

Aca­d­e­m­ic tri­al sug­gests mod­est GLP-1 ef­fect in Parkin­son's dis­ease, but ques­tions re­main

Last year
R&D

Mer­ck KGaA inks ADC dis­cov­ery deal with AI tech­bio worth up to $1.4B in mile­stones

Last year
Deals
R&D

Ex­clu­sive: PBM uni­corn start­up Right­way rais­es $109M, ac­cord­ing to fil­ing

Last year
Health Tech

FDA ap­proves Basilea’s an­tibi­ot­ic for se­vere bac­te­r­i­al in­fec­tions

Last year
Pharma
FDA+

WuXi builds out lob­by­ing bench amid leg­isla­tive ef­fort to black­list com­pa­ny

Last year
China
Pharma

Q&A: Gen­mab CEO on ink­ing the first ac­qui­si­tion in the com­pa­ny's 25-year his­to­ry

Last year
Deals
Pharma

Har­ris Poll notes in­crease in phar­ma rep­u­ta­tion among Amer­i­cans who know about GLP-1 drugs

Last year
Pharma
Marketing

Biden’s plan for hos­pi­tals to pay more for drugs in short­age is ‘mis­guid­ed,’ group says

Last year
Pharma
Manufacturing

'We beat big phar­ma': Biden ap­plauds IRA, calls for ex­pan­sion of Medicare ne­go­ti­a­tions

Last year
Pharma
FDA+

As Mer­ck KGaA grows South Ko­re­an foot­print, it al­so ze­roes in on re­gion­al man­u­fac­tur­ing

Last year
Manufacturing

LENZ plans NDA sub­mis­sion for pres­by­opia eye drops this year, looks to launch in 2025

Last year
R&D

Ob­sid­i­an Ther­a­peu­tics rakes in $160M for sol­id tu­mor cell ther­a­py pro­gram

Last year
Financing
Cell/Gene Tx
First page Previous page 176177178179180181182 Next page Last page
A service from the Financial Times